article thumbnail

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

STAT

Keytruda is a cancer immunotherapy, which stimulates the immune system to attack tumor cells and is the best-selling medicine in the world. patent expires in 2028. The subcutaneous injection could be given in a doctor’s office every six weeks, instead of requiring a 30-minute IV drip at the same interval.

article thumbnail

Lupin receives tentative U.S. FDA approval for Raltegravir tablets

Express Pharma

Lupin, a global pharmaceutical company, has announced its tentative approval from the United States Food and Drug Administration (U.S. This medication targets the virus, aiming to lower viral load and improve immune function in affected individuals. according to IQVIA data for the 12 months ending September 2024.

Immunity 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck’s latest deal turns up the spotlight on immune system drugmakers

BioPharma Dive

The buyout of Prometheus highlights pharmaceutical companies’ intense interest in medicines targeting inflammatory diseases, according to analysts.

Immunity 116
article thumbnail

It’s Code Red for Vaccines in America

NY Times

s Advisory Committee on Immunization Practices. s independent scientific body on immunization. This is despite promising early data on the effectiveness of the company’s bird flu vaccine, and an urgent need for more pandemic response tools. The firing of the A.C.I.P. The committee has served for decades as the C.D.C.’s

Vaccines 134
article thumbnail

Tetra and Cellvera partner to develop oral Covid-19 treatment

Pharmaceutical Technology

It is claimed to have outperformed an antiviral drug in lowering various proinflammatory mediators linked to hyperinflammation and dysfunction of the immune system after viral infection. Qifenda is a broad-spectrum antiviral drug in the commercial stage. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera.

Immunity 132
article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

article thumbnail

Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy

Pharmaceutical Technology

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

Immunity 104